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Summary
 
The local production of proinflammatory cytokines mediates the host response to inflamma-
tion, infection, and injury, whereas an overexpression of these mediators can injure or kill the
host. Recently, we identified a class of multivalent guanylhydrazone compounds that are effective
inhibitors of proinflammatory cytokine synthesis in monocytes/macrophages. The structure of
one such cationic molecule suggested a molecular mimicry with spermine, a ubiquitous endog-
enous biogenic amine that increases significantly at sites of inflammation and infection. Here,
we addressed the hypothesis that spermine might counterregulate the innate immune response
by downregulating the synthesis of potentially injurious cytokines. When spermine was added
to cultures of human peripheral blood mononuclear cells stimulated with lipopolysaccharide
(LPS), it effectively inhibited the synthesis of the proinflammatory cytokines tumor necrosis
factor (TNF), interleukin-1 (IL-1), IL-6, MIP-1
 
a
 
, and MIP-1
 
b
 
. The inhibition of cytokine
synthesis was specific and reversible, with significant inhibition of TNF synthesis occurring
even when spermine was added after LPS. The mechanism of spermine-mediated cytokine
suppression was posttranscriptional and independent of polyamine oxidase activity. Local ad-
ministration of spermine in vivo protected mice against the development of acute footpad in-
flammation induced by carrageenan. These results identify a distinct molecular counterregula-
tory role for spermine in downregulating the monocyte proinflammatory cytokine response.
 
D
 
uring the early immune response to infection or in-
jury, macrophages synthesize proinflammatory cyto-
kines, which orchestrate the inflammatory reaction. Rela-
tively small amounts of these cytokines produced locally in
tissues benefit the host by activating antimicrobial pathways
and stimulating tissue repair. Evidence of these protective
mechanisms has been obtained in animal studies, where ad-
ministration of anti-TNF antibodies worsens the severity
and duration of Leishmania infection in mice (1), and mice
rendered insensitive to TNF by knockout of TNF recep-
tors are exquisitely sensitive to infection by intracellular
pathogens (2). On the other hand, the uncontrolled release
of larger amounts of cytokines, and the resultant mediator
cascade, signals the onset of tissue injury and lethal shock
(3–5). This potentially disastrous scenario is normally pre-
vented by endogenous counterregulatory mechanisms that
have evolved to inhibit cytokine overproduction. One class
of endogenous cytokine synthesis inhibitors are the gluco-
corticoid hormones, which are produced during the stress
response, and suppress immune activation and cytokine
synthesis (6, 7). Another class is comprised of the anti-
inflammatory cytokines (e.g., TGF-
 
b
 
 and IL-10), which
effectively inhibit macrophage activation and proinflamma-
tory cytokine synthesis and prevent the injurious sequelae
of cytokine excess (8–12). Lastly, prostaglandin E2, which
accumulates at sites of inflammation, can also suppress TNF
synthesis by increasing intracellular cAMP (13, 14). To-
gether, these molecular mechanisms serve to counterregu-
late or dampen the inflammatory response, and to prevent
the overabundant production of potentially injurious cy-
tokines during the immune response to invasive stimuli.
The present study originated from our recent work fo-
cused on a class of low molecular weight multivalent gua-
nylhydrazone compounds that suppress proinflammatory
cytokine synthesis in activated monocytes/macrophages
(15, 16). One of these, N,N
 
9
 
-bis[3,5-bis [1(amino-imi-
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nomethyl)hydrazono]-ethyl]phenyl]-decanediamide tetrahy-
drochloride (termed CNI-1493) effectively inhibits TNF
translation and suppresses the production of the pro-inflam-
matory cytokines IL-1, IL-6, MIP-1
 
a
 
, and MIP-1
 
b
 
 in hu-
man PBMCs (16, 17). Inhibition of proinflammatory cytokine
synthesis by CNI-1493 is specific, because CNI-1493 does
not inhibit synthesis of the anti-inflammatory cytokine TGF-
 
b
 
,
nor does it prevent the upregulation of MHC class II induced
by IFN-
 
g
 
 (16). By suppressing proinflammatory cytokine
production in vivo, CNI-1493 protects mice against the
lethal effects of endotoxin, and prevents the acute inflamma-
tory response in carrageenan-induced footpad edema (15,
16). We considered it plausible that the cytokine inhibitory
activities of this cationic anti-inflammatory molecule might
be attributable to molecular mimicry with an endogenous
molecule(s) that normally participates in counterregulating
cytokine production.
Spermine, a ubiquitous biogenic amine that is positively
charged at physiological pH, has been widely studied for its
biological roles in the regulation of DNA synthesis, cellular
proliferation, modulation of ion channel function, and as a
second messenger in cellular signaling (18). A large body of
evidence also implicates spermine as an inhibitor of im-
mune responses. For example, spermine prevents nitric oxide
(NO)
 
1
 
 production in macrophages activated by bacterial en-
dotoxin (19, 20), downregulates human neutrophil locomo-
tion (21), and is immunosuppressive to T cells (22). In-
creased spermine levels have been measured in tissues
following injury, inflammation, and infection, derived in
part from the release of intracellular spermine from dying
and injured cells, and in part by stimulated biosynthesis
(23). It has been suggested that the accumulation of sper-
mine, and the products of its oxidative metabolism via
polyamine oxidase, mediate the anti-inflammatory activity
found in inflammatory exudates, human pregnancy serum,
plasma from arthritic rats, and human rheumatoid synovial
fluid (21, 24–28). Although these and other studies impli-
cate spermine in suppressing the innate immune response,
it was unclear whether it might also counterregulate proin-
flammatory cytokine synthesis.
We show here that spermine effectively suppresses the
synthesis of proinflammatory cytokines in human PBMCs.
The mechanism of cytokine inhibition by spermine was post
transcriptional, reversible, specific, and independent of poly-
amine oxidase activity. The in vivo application of spermine
protected mice against the development of carrageenan-
induced edema, giving evidence that spermine accumulation
in tissues can counterregulate the acute inflammatory response.
 
Materials and Methods
 
Cell Isolation and Culture.
 
Human PBMCs were obtained by
elutriation from normal individual donors to the Long Island Blood
Bank services (Melville, NY). PBMCs were isolated by density
gradient centrifugation through Ficoll (Ficoll–Paque PLUS, Phar-
macia, Piscataway, NJ) as previously described (16, 29) with a yield
typically of 2 
 
3
 
 10
 
8
 
 adherent cells per isolation. Cells were resus-
pended in RPMI-1640 (GIBCO BRL, Gaithersburg, MD) sup-
plemented with 10% heat-inactivated human serum, 0.1% 
 
l
 
-glut-
amine, and 0.01% gentamicin, seeded into either 24-well (at 5 
 
3
 
10
 
6
 
 cells/well, for RNA isolation) or 96-well plates (at 5 
 
3
 
 10
 
5
 
cells/well, for spermine uptake and cytokine assays), and cultured
overnight at 37
 
8
 
C in a humidified atmosphere of 5% CO
 
2
 
 and
95% air. Nonadherent cells were removed after overnight culture,
and adherent cells (monocytes) were subjected to different experi-
mental treatments as indicated. For studies of murine macro-
phage-like cells, RAW264.7 cells were obtained from the Amer-
ican Type Culture Collection (ATCC, Rockville, MD), seeded
into 24-well tissue culture plates (1 
 
3
 
 10
 
6
 
 cells/ml RPMI 1640,
10% FBS, 2 mM glutamine) and subjected to experimental treat-
ments as described for human PBMCs.
 
Cytokine Induction.
 
To stimulate cytokine production from
human PBMCs, freshly sonicated 
 
Escherichia coli
 
 endotoxin (LPS;
Sigma Chem. Co., St. Louis, MO) was added to a final concen-
tration of 100 ng/ml. In some experiments, IFN-
 
g
 
 (Boehringer
Mannheim, Indianapolis, IN) was also added to a final concentra-
tion of 25 U/ml. To evaluate the effect of spermine on produc-
tion of cytokines from the stimulated human PBMCs, freshly pre-
pared spermine (Sigma) was added to human PBMCs at various
concentrations 1 h before LPS/IFN-
 
g
 
 stimulation. After LPS/IFN-
 
g
 
stimulation, supernatants were harvested and assayed for level of
cytokines by ELISA assays. Lactate dehydrogenase (LDH) release,
trypan blue exclusion, and metabolism of MTT were used to
evaluate cytotoxicity.
 
Cytokine Assay.
 
TNF levels in supernatants and cell lysates of
human PBMCs were determined by ELISA using monoclonal
and polyclonal antibodies raised against human TNF (Picower In-
stitute for Medical Research, Manhasset, NY). Serial dilution of
recombinant human TNF (0–10,000 pg/ml) was used in ELISA
to generate standard curves. In brief, 96-well microtiter plates were
coated with 60 
 
m
 
l of supernatants or standard hTNF solution at
4
 
8
 
C for 8–18 h (or at 37
 
8
 
C for 2 h). After washing with buffer
containing 20 mM Tris–HCl (pH 
 
5
 
 7.4), 150 mM NaCl, and
0.05% Tween 20, 60 
 
m
 
l of polyclonal TNF antibodies diluted (at
1:200) in buffer containing 10 mM Tris–HCl (pH 
 
5
 
 7.4), 150
mM NaCl, 0.2% Tween 20, and 1% goat serum was added and
incubated at room temperature for 2 h. After several washings
to remove the unbound antibodies, the bound antibodies were
then reacted for 30 min with 60 
 
m
 
l (1:2,500 dilution) alkaline
phosphatase–conjugated goat anti–rabbit IgG (H
 
1
 
L) (Boehringer
Mannheim, Indianapolis, IN). After washing, the amount of spe-
cifically bound alkaline phosphatase-conjugated antibodies was
determined by assaying for alkaline phosphatase activity with
freshly prepared p-nitrophenylphospate in diethanolamine buffer
(10 mM diethanolamine and 0.5 mM MgCl
 
2
 
, pH 
 
5
 
 9.5). A sub-
strate solution was added into each well and incubated for 30 min
at room temperature. The absorption at 405 nm was determined
with a automatic EIA analyzer. MIP-1
 
a
 
 and MIP-1
 
b
 
 levels were
determined by specific sandwich ELISA as previously described
(30), with the exception that coating (goat) and revealing (rabbit)
antibodies specific for human MIP-1
 
a
 
 and human MIP-1
 
b
 
 were
used. IL-1
 
b
 
, IL-6, and TGF-
 
b
 
 levels were determined by com-
mercially obtained ELISA kits according to the instructions of the
manufacturer (Genzyme, Cambridge, MA). Cell lysates were pre-
pared in lysis buffer (50 mM Tris–HCl, 0.5% NP-40, 150 mM
NaCl, 5 mM EDTA, 1 mM PMSF, 10 
 
m
 
g/ml leupeptin, 10 
 
m
 
g/ml
pepstatin, 0.02% sodium azide, pH 7.4).
 
1
 
Abbreviations used in this paper:
 
 iNOS, inducible nitric oxide synthase;
LDH, lactate dehydrogenase; NO, nitric oxide; PKC, protein kinase C. 
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Total RNA Isolation and Northern Blotting.
 
Total RNA was iso-
lated from human PBMCs by using the BRL TRIzol reagent kit
as instructed by the manufacturer (GIBCO BRL, Gaithersburg,
MD), separated on a 1% agarose gel with 2.2 M formaldehyde,
and subsequently transferred to Biotrans nylon membrane (ICN,
Aurora, Ohio). After UV cross-linking (at 150 mJ), the mem-
brane was prehybridized at 45
 
8
 
C for 2 h in hybridization buffer
containing 5
 
3
 
 Denhardt’s, 5
 
3
 
 SSC, 50 mM NaH
 
2
 
PO
 
4
 
, 0.1%
SDS, 50% formamide and 250 
 
m
 
g/ml salmon sperm DNA, and
subsequently hybridized overnight at 45
 
8
 
C with [
 
32
 
P]dCTP–
labeled TNF or MIP-1
 
a
 
 cDNA probes (using Radprime DNA
Labeling System from BRL) in the same hybridization buffer. Af-
ter two washings at room temperature for 20 min with 2
 
3
 
 SSC,
0.1% SDS, two washings at room temperature for 20 min with
0.5
 
3
 
 SSC, 0.1% SDS, and a final washing at 60
 
8
 
C for 30 min
with 0.1
 
3
 
 SSC, 0.1% SDS, the membrane was exposed to X-ray
film at 
 
2
 
70
 
8
 
C overnight and developed to visualize the signal.
Level of TNF protein in the supernatants of human PBMCs were
determined by ELISA for comparison to the corresponding TNF
mRNA level.
 
Carrageenan-induced Footpad Inflammation.
 
Paw edema was in-
duced by injecting 50 
 
m
 
l 
 
l
 
-carrageenan (0.2% in phosphate buffer
[1
 
3
 
 PBS, pH 7.4]; Sigma, St. Louis, MO), into the plantar sur-
face of the left hind footpad of female C3H/HeN mice (20–25 g
body weight) either alone, or in combination with various con-
centrations of spermine. The right hind footpad was injected with
50 
 
m
 
l of PBS as control. 28 h after footpad injection, the thick-
ness of the carrageenan- and saline-injected footpad was measured
using calipers, and the data expressed as the difference between
the diameters of the two footpads.
 
Results
 
Spermine Suppression of TNF Synthesis in LPS-activated
Human PBMCs.
 
To study the effect of spermine on TNF
synthesis, human PBMCs purified by elutriation and adher-
ence were stimulated with LPS (100 ng/ml). Whereas LPS
is a potent inducer of TNF synthesis in these cells, pretreat-
ment with spermine (60 min before LPS challenge) effec-
tively suppressed LPS-induced TNF synthesis (Fig. 1). The
50% inhibitory concentration (IC
 
50
 
) of spermine for TNF
protein release was 20 
 
6
 
 15 
 
m
 
M. Maximal TNF suppres-
sion was observed with spermine concentrations 
 
>
 
100 
 
m
 
M,
which suppressed TNF production to levels that were 25–
35% of the TNF levels produced by controls. Spermine did
not interfere with ELISA detection of TNF as evidenced
by the fact that TNF standard curves measured in the pres-
ence of spermine were comparable to TNF standard curves
measured in its absence (data not shown). Moreover, TNF
levels as assessed by the L929 cell cytotoxicity bioassay were
also inhibited by addition of spermine (data not shown).
Although the purified human PBMCs contained more than
95% monocytes, we wished to confirm that spermine in-
hibited TNF production in the murine macrophage-like
cell line RAW 264.7. In these experiments, we observed
that spermine inhibited LPS-induced TNF synthesis in
RAW cells, and that the IC
 
50
 
 was 40 
 
6
 
 20 
 
m
 
M, a value com-
parable (
 
P
 
 
 
.
 
0.05) to the IC
 
50
 
 determined in human PBMCs
(see above).
We next studied the kinetics of spermine-mediated sup-
pression of TNF synthesis in human PBMCs. In agreement
with previous results showing that TNF is released within 2 h
after stimulation of monocytes with LPS (31), pretreatment
of monocytes with spermine before LPS, or coadministra-
tion of spermine simultaneously with LPS, was maximally
effective in suppressing TNF synthesis (Table 1). However,
significant inhibition was also observed, when spermine was
added for up to 2 h after LPS (Table 1). To explore whether
spermine-treated monocytes were capable of recovering
the ability to synthesize TNF after spermine removal, we
measured TNF production by human PBMCs that were
incubated with spermine (35 
 
m
 
M) for 1 h, washed with
PBS, and then incubated in fresh media without added
spermine. TNF synthesis by washed PBMCs remained sig-
nificantly decreased for up to 4 h after spermine removal
from the cellular milieu (4-h washout, TNF 
 
5
 
 1580 
 
6
 
 376
pg/ml; control TNF 
 
5
 
 3694 
 
6
 
 214 pg/ml, 
 
P
 
 
 
,
 
0.05). By
24 h after removing spermine, TNF synthesis was fully re-
covered to a level (TNF 
 
5
 
 3211 
 
6
 
 151 pg/ml) that was
comparable to PBMCs that had never been exposed to
spermine. Although recovery of TNF synthetic function by
spermine-treated cells indicated that the mechanism of sper-
mine inhibition of TNF synthesis could not be attributed
to cytotoxicity, we also measured LDH release to assess cell
viability. LDH activity was not increased in the media of
spermine treated cells, even when spermine was added in
concentrations exceeding 100-fold the IC
 
50
 
 for TNF sup-
pression ([spermine, 3 mM] LDH 
 
5
 
 18 
 
6
 
 15 U/ml; versus
controls [spermine, 0 mM] LDH 
 
5
 
 21 
 
6
 
 10 U/ml). Sepa-
rate experiments using trypan blue exclusion and metabo-
lism of MTT also confirmed that spermine concentrations
>3 mM were not toxic to human PBMCs during a 4 h
treatment (data not shown).
Figure 1. Spermine inhibits TNF synthesis from LPS-stimulated hu-
man PBMCs. Human PBMCs were exposed to the concentrations of
spermine as indicated for 1 h, then stimulated by addition of LPS (100
ng/ml) and IFN-g. TNF released into the conditioned supernatants col-
lected after 4 h was measured by ELISA and results expressed as percent-
age of control (no spermine). Data shown are mean 6 SEM of three in-
dependent experiments. (Control TNF 5 7416 6 763 pg/ml.)1762 Spermine Counterregulates Proinflammatory Cytokines
Spermine Suppression of TNF Is Posttranscriptional and Spe-
cific.  The mechanism of spermine action on cytokine
synthesis was initially investigated by Northern blot analysis
of total RNA extracted from LPS-activated human PBMCs
using [32P]dCTP–labeled TNF and MIP-1a cDNA as
probes. In agreement with previous results (17), TNF and
MIP-1a mRNA were not detected in human PBMCs in
the absence of LPS, but were significantly increased 2 h af-
ter addition of LPS (100 ng/ml) (Fig. 2). Steady state levels
of TNF and MIP-1a mRNA were not decreased by addi-
tion of spermine at a concentration (35 mM), although
TNF and MIP-1a protein synthesis in the same cell cul-
tures was suppressed to a level that was just 25 and 8% of
controls, respectively (P ,0.05) (Fig. 3, a and c). We ob-
tained similar results in separate experiments using quanti-
tative PCR methodology in which the steady state level of
TNF mRNA was found to be comparable between sper-
mine-treated (35 mM) and untreated LPS-stimulated PBMCs,
whereas spermine inhibited TNF protein synthesis in the
same cells (data not shown).
To define further the posttranscriptional action of sper-
mine on the release of TNF and MIP-1a, we assayed the
cellular levels of these cytokines in lysates of LPS-stimu-
lated cells. Exposure of human PBMCs to spermine signifi-
cantly inhibited the levels of cell-associated TNF and MIP-1a
(Fig. 3, b and d). We observed a similar IC50 for spermine
inhibition of cell-associated and secreted cytokine levels.
Because the levels of cell-associated cytokines were dimin-
ished and not increased, these results provide direct evidence
that the mechanism of spermine action is by inhibiting cyto-
kine synthesis, and not through suppressing cytokine re-
lease.
The specificity of spermine inhibition of proinflamma-
tory cytokine synthesis was determined by measuring the
levels of other macrophage-derived cytokines in the super-
natants of LPS-activated human PBMCs. We observed sper-
mine dose-dependent suppression of the proinflammatory
cytokines MIP-1b, IL-1b, and IL-6, from LPS-activated
human PBMCs (Fig. 4). The IC50 for spermine inhibition
for each of these four proinflammatory cytokines was z2
mM, with maximal suppression of MIP-1a, MIP-1b, and
IL-6 exceeding 90%. However, the effects of spermine on
IL-1b synthesis differed somewhat from these other cyto-
kines, because at saturating spermine concentrations, IL-1b
synthesis was only decreased by 65% as compared with
controls. The residual amount of IL-1b synthesis (35%) that
could not be inhibited by spermine treatment was similar
to the residual amount of TNF synthesis that persisted in
the presence of spermine (see above). Additional evidence
for the specificity of spermine inhibition of proinflamma-
tory cytokine synthesis was given by the observation that
spermine failed to suppress the constitutive production of
TGF-b from human PBMCs (Fig. 4 d), even when sper-
mine was added in concentrations more than 100-fold
higher than the IC50 for the proinflammatory cytokines.
When considered together, these results indicate that sper-
mine specifically and reversibly inhibits proinflammatory
cytokine synthesis in human PBMCs.
Spermine Inhibits TNF Synthesis in Serum-free Media and in
the Presence of Polyamine Oxidase Inhibition. Szabo and co-
workers (19, 20, 32) recently reported that spermine sup-
pressed the induction of inducible nitric oxide synthase
(iNOS) in the cell line J774.2, and found that the molecu-
lar basis for this suppression was dependent upon oxidation
of spermine by polyamine oxidase present in bovine serum.
To address the possible role of polyamine oxidase-mediated
spermine oxidation in the mechanism of spermine action
on inhibiting proinflammatory cytokine synthesis in pri-
mary human monocytes, we measured TNF production in
human PBMCs that had been cultured and stimulated with
LPS under serum-free conditions. We observed a spermine
dose-dependent suppression of TNF in the absence of
added serum (Fig. 5 a), and determined that the IC50 under
Table 1. Kinetics of Spermine-mediated Inhibition of TNF 
Synthesis from LPS and IFN-g-stimulated Human PBMCs
Time of spermine addition (min)* TNF (percent of controls)
No spermine added 100
260 26 6 2
230 26 6 4
25 33 6 3
0 28 6 3
15 21 6 3
130 52 6 7
160 49 6 8
1120 66 6 7
*LPS and IFN-g were added at time 0. Spermine (35 mM) was added
at the relative times shown, and TNF in supernatants conditioned for 4
h after LPS was detected by ELISA. Data are mean 6 SEM from six
replicates of an experiment that was repeated twice.
Figure 2. Spermine suppres-
sion of TNF and MIP-1a is
posttranscriptional in LPS-stimu-
lated human PBMCs. Northern
blots for TNF and MIP-1a in
human PBMCs performed 4 h
after stimulation by LPS (100
ng/ml). Where indicated, sper-
mine (35 mM) was added 1 h be-
fore LPS. Results are representa-
tive of two separate experiments
using 6 mg of total RNA applied
per lane.1763 Zhang et al.
serum-free conditions was similar to that measured in se-
rum-containing media (serum-free IC50 5 8 6 4 mM) ver-
sus serum-containing media (10% FBS IC50 5 20 6 15
mM; P .0.05). Although these experiments suggested that
oxidation of spermine by polyamine oxidase was not re-
quired for TNF suppression in human PBMCs, we wished
to confirm this interpretation by adding a pharmacological
inhibitor of polyamine oxidase to serum-containing media
and then measuring the effect of spermine on TNF synthe-
sis. In these experiments, we measured spermine oxidase
activity in bovine serum–containing media using HPLC
detection of spermine, and in agreement with previous re-
sults (33), addition of aminoguanidine (2 mM) suppressed
enzyme activity to ,1% of controls. In these conditions of
complete enzyme inhibition we also observed a spermine
dose-dependent suppression of TNF synthesis (Fig. 5 b).
The IC50 for spermine inhibition of TNF in the presence
of complete polyamine oxidase inhibition with aminoguani-
dine (IC50 5 8 6 6 mM) was similar to that observed in
controls, as measured in serum-containing media without
addition of aminoguanidine (IC50 5 20 6 15; P .0.05).
Although these results suggested that spermine oxidation is
not required for the cytokine suppressing activity of sper-
mine, we wished to control for the possibility that an alterna-
tive oxidative mechanism might have resulted in the forma-
tion of spermidine in these cultures. Accordingly, we
assessed the effects of spermidine on LPS-stimulated TNF
synthesis. Although we did observe spermidine to inhibit
TNF synthesis in human PBMCs, the measured IC50 (638 6
143 mM) was significantly higher than for spermine itself
(P .0.05), suggesting that metabolism of spermine to sper-
midine is not the molecular basis for the observed cytokine
inhibition by spermine. When considered together, these
results indicate that the inhibition of proinflammatory cy-
tokine synthesis in human PBMCs is directly attributable to
spermine, and is not dependent upon the activity of poly-
amine oxidase.
Administration of Spermine In Vivo Suppresses Carrageenan-
mediated Inflammation. The observations that spermine de-
creases proinflammatory cytokine production by LPS-stim-
ulated human monocytes suggested that local accumulation
of spermine at inflammatory sites could suppress the devel-
opment of cytokine-mediated tissue responses. We investi-
gated this mechanism in vivo by measuring the develop-
ment of edema induced by injection of carrageenan into
the footpad of mice, a widely used model of inflammation
in which cytokine antagonists and other anti-inflammatory
agents can effectively suppress the inflammatory response
Figure 3. Spermine inhibition of TNF and MIP-1a protein in cell lysates and supernatants.Human PBMCs were exposed to spermine for 1 h, stimu-
lated with LPS, and after 4 h of stimulation lysed as described in Materials and Methods. The levels of TNF and MIP-1a in the supernatants (a and c) and
corresponding whole-cell lysates (b and d) are shown. Data are mean 6 SEM.1764 Spermine Counterregulates Proinflammatory Cytokines
(15, 34, 35). Administration of spermine directly into the
carrageenan-injected paw significantly suppressed the de-
velopment of swelling (Fig. 6). The anti-inflammatory effects
were spermine dose-dependent, and maximally inhibited
footpad swelling by 48% as compared with vehicle-treated
controls (P ,0.05). Because the development of acute
edema in this model is dependent upon the activity of cy-
tokines (and independent of LPS), these results now suggest
that the local accumulation of spermine in tissues can sup-
press the development of injurious inflammation in vivo.
Discussion
Some 44 years ago, a search for a natural product in ani-
mal tissues capable of suppressing the growth of tubercle
bacilli ultimately led Hirsch and Dubos to discover that
spermine was the active anti-mycobacterial principle (36).
This seminal work revealed a potential mechanism through
which the cytotoxic activity of a ubiquitous polyamine could
protect the host during invasive infection. Because it was
already known that spermine concentrations were signifi-
cantly elevated in tissues during infectious, neoplastic, and
inflammatory diseases (e.g., tuberculosis, pneumonia, can-
cer), they proposed a direct role for spermine in limiting
the growth or spread of an infectious agent or tumor (36).
Our present results now support an additional mechanism
by which spermine can participate in the host response to
infection or invasion, by counterregulating proinflamma-
tory cytokine synthesis.
The proinflammatory cytokines TNF, IL-1, IL-6, MIP-
1a, and MIP-1b occupy a pivotal role in stimulating the
early stages of acute inflammation, including recruitment and
activation of inflammatory cells, stimulation of endothelial
cell activation, and direct cytotoxicity (5, 37–39). Whereas
these inflammatory events can be critical to the ultimate re-
covery from infection or injury, normal counterregulatory
mechanisms are also critical to the success of the immune
response, because the inappropriate or excessive produc-
tion of proinflammatory cytokines ultimately can lead to
the development of shock and tissue injury (3, 4, 40). Pre-
viously, extensive investigations of counterregulatory im-
mune mechanisms have focused on the cytokine inhibitory
roles of the glucocorticoid hormones, the anti-inflamma-
tory cytokines TGF-b and IL-10, and the prostaglandin
PGE2 (8–12, 14, 41–43). Together, these studies demon-
strate the critical central role occupied by counterregulating
signals that serve to dampen the immune response. The
present results now indicate that spermine counterregula-
Figure 4. Spermine inhibition of MIP-1b, IL-1b, and IL-6, but not TGF-b from human PBMCs. Human PBMCs were pretreated with spermine for
60 min, then stimulated with LPS (100 ng/ml). 4 h after LPS treatment, supernatants were assayed by ELISA for: a MIP-1b; b IL-1b; c IL-6; and d TGF-b.
Data are mean 6 SEM of three experiments. Control cytokine levels: MIP-1b, 19 ng/ml; IL-1b, 32 pg/ml; IL-6, 6,000 pg/ml; and TGF-b, 680 6 133
pg/ml.1765 Zhang et al.
tion of proinflammatory cytokine production offers an-
other level of molecular regulation capable of reducing the
injurious activity of a local immune response.
In agreement with its proposed cytokine counterregula-
tory role, spermine-mediated cytokine inhibition was spe-
cific, reversible, and time dependent, therefore enabling an
innate mechanism in which the affected monocytes can re-
cover their cytokine producing function to participate in
subsequent immune responses. Because spermine effec-
tively inhibited cytokine synthesis in serum-free conditions,
and in the presence of the polyamine oxidase inhibitor
aminoguanidine, oxidative metabolism of spermine is not
required for the molecular mechanism of cytokine coun-
terregulation. Spermine levels required to suppress cyto-
kine synthesis are readily achieved in vivo, because high
tissue concentrations (500 mM to 2 mM) have been re-
ported in tumors, and in patients infected with bacteria,
mycobacteria, and viruses (36, 44–47). Because elevated
polyamine levels have also been implicated in the immuno-
suppressive state associated with pregnancy and fetal devel-
opment (24, 48, 49), it is now interesting to consider
whether the mechanism of immunosuppression in these
earlier observations is attributable at least in part to sper-
mine-mediated counterregulation of proinflammatory cy-
tokines. For instance, elevated spermine levels found in
amniotic fluid might dampen the production of TNF and
IL-1b, and thereby prevent the onset of abortion mediated
by cytokine release in the amnion (50). The present study
did not address the role of spermine on T cell cytokine
synthesis, but earlier work by Flescher and colleagues (51)
suggested that spermine does not inhibit IL-2 production
in PHA-stimulated monocytes. Rather, inhibition of IL-2
synthesis was observed by a combination of spermidine,
polyamine oxidase, and hydrogen peroxide, leading them
to conclude that oxidative metabolism of spermidine, but
not spermine, can inhibit T cell IL-2 production (51). In
contrast, we found that spermidine was a poor inhibitor of
monocyte/macrophage proinflammatory cytokine synthe-
sis, and that spermine was an effective inhibitor even in the
absence of polyamine oxidase activity. When considered to-
gether, these findings now suggest that spermine suppres-
sion of monocyte proinflammatory cytokine synthesis is spe-
cific and direct.
Figure 5. Spermine suppression of TNF synthesis in serum-free media and in the presence of polyamine oxidase inhibition. (a) PBMCs were cultured
in serum-free media (OPTI-MEMI), stimulated with LPS for 4 h, then TNF levels in the media measured by ELISA as described. (b) Human PBMCs
were cultured in RPMI-1640 containing FBS (10%) with the addition of aminoguanidine (0, 1, or 2 mM) as shown. 4 h after LPS treatment, conditioned
supernatants were assayed for TNF by ELISA as described above.The data shown are from a representative experiment (repeated twice with similar re-
sults). Each point represents mean 6 SEM from six replicates.
Figure 6. Spermine suppresses carrageenan-induced inflammation in
mice. Carrageenan (0.2%) was injected into the left rear footpad of C3H/
HeN mice with the concentration of spermine indicated in 50 ml; ; vehicle
(13 PBS) was injected into the right hindpaw. 28 h later, the footpad
thickness was measured with a caliper, and the difference between right
and left hindpaw determined. Data are mean 6 SEM (mm) from three
experiments, with n 5 5 animals in each experimental group.1766 Spermine Counterregulates Proinflammatory Cytokines
It will be of interest to investigate whether spermine
inhibition of cytokine translation is dependent upon cellu-
lar signaling pathways that are shared with other cytokine
counterregulators, and whether they converge on some key
regulatory step(s). We have considered the hypothesis that
spermine might act via a molecular pathway shared with
the glucocorticoids, but the following observations suggest
that spermine-mediated cytokine counterregulation is inde-
pendent of glucocorticoid signaling. (a) Spermine inhibition
of TNF and MIP-1a occurs posttranscriptionally, whereas
glucocorticoids inhibit both transcription and translation
(7); (b) spermine retains its counterregulatory activity in the
presence of IFN-g, but IFN-g overrides the suppressive ac-
tivity of glucocorticoids (52); and (c) the recovery of mono-
cyte TNF synthesis in spermine washout experiments is more
rapid than that predicted for glucocorticoid-mediated inhi-
bition (53). These observations suggest that spermine-
mediated cytokine counterregulation occurs by a molecular
pathway that is distinct from glucocorticoids. It will also be
of interest to address whether the inhibitory effects of sper-
mine in monocytes/macrophages are dependent upon an as
yet unidentified monocyte/macrophage receptor or bind-
ing protein at the cell surface, and whether spermine trans-
port into the monocyte/macrophage is required for inter-
action with an intracellular target.
Previous studies indicate that LPS stimulation of mono-
cytes activates spermine uptake via a protein kinase C (PKC)–
dependent mechanism (15, 54–57). In agreement with these
results, we have observed enhanced spermine uptake after
LPS stimulation in human PBMCs (data not shown). It is
plausible that LPS-stimulated spermine uptake can partici-
pate in the observed suppression of proinflammatory cytokine
synthesis. It should be noted that the action of spermine in
suppressing cytokine synthesis is not simply attributable to
neutralizing LPS via a charge effect, because LPS-stimu-
lated signaling in the presence of spermine still produced
significant increases in the levels of TNF and MIP-1a
mRNA (Fig. 2). Moreover, spermine effectively suppressed
the development of edema induced by carrageenan in vivo,
an acute inflammatory response that is dependent upon cy-
tokine production but independent of LPS (15, 34, 35).
Spermine counterregulation of proinflammatory cyto-
kine synthesis was specific, because the suppression of MIP-
1a, MIP-1b, and IL-6 approached 100%, but maximal sup-
pression of TNF and IL-1b failed to exceed 75%. In further
agreement with its proposed role as an anti-inflammatory
mediator, spermine failed to suppress TGF-b, a potent anti-
inflammatory cytokine (8). Consideration of these results leads
to the appreciation that TNF and IL-1b each occupy pivotal
beneficial roles in the immune response, so that the pro-
posed mechanism of spermine in differentially counterreg-
ulating cytokine release also enables the continued produc-
tion of beneficial, or perhaps necessary, low levels of these
two mediators. Even in the presence of the very high sper-
mine levels found in diseased tissues, low level production
of TNF and IL-1 could persist to benefit the host by stim-
ulating antimicrobial and antiviral immune responses,
promoting tissue regeneration, and facilitating wound heal-
ing (5). Meanwhile, the uninhibited release of TGF-b can
participate in further counterregulation and containment of
the local immune response.
We conclude that spermine counterregulation of cyto-
kine production is a mechanism for locally suppressing the
acute, and potentially injurious tissue response to inflam-
mation in vivo. Because spermine is released from dying
and injured cells during infection, injury, ischemia, and
inflammation, it is suitably positioned as a feedback signal
to suppress further damage from cytokine excess. Tissue
spermine levels predictably reflect the extent of surround-
ing tissue injury, thereby providing a sensitive counterreg-
ulatory signal to prevent excessive activation of macro-
phages. This molecular counterregulatory feedback loop
would be anticipated to predominate locally at tissue sites
of inflammation, and not systemically as is the case with the
glucocorticoids and the anti-inflammatory cytokines.
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